New hope for tough leukemia: experimental drug AZD0486 enters human trials
NCT ID NCT06137118
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called AZD0486 in adolescents and adults whose B-cell acute lymphoblastic leukemia (B-ALL) has returned or not responded to at least two prior treatments. The trial has three parts: first, finding a safe dose; second, optimizing that dose; and third, testing the best dose in a larger group. The main goals are to check safety and see if the drug can achieve complete remission within three cycles of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AZD0486 (a drug given by IV infusion)
- What this could lead to
- If it works, this could offer a new treatment option for people with B-cell acute lymphoblastic leukemia that has come back or not responded to other therapies.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with only 236 participants, so the drug may not prove effective or safe enough for wider use. Side effects, including serious ones, are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
WITHDRAWNBirmingham, Alabama, 35233, United States
-
Research Site
RECRUITINGDuarte, California, 91010, United States
-
Research Site
RECRUITINGLos Angeles, California, 90048, United States
-
Research Site
RECRUITINGPalo Alto, California, 94304, United States
-
Research Site
RECRUITINGTampa, Florida, 33612, United States
-
Research Site
RECRUITINGAtlanta, Georgia, 30322, United States
-
Research Site
RECRUITINGChicago, Illinois, 60637, United States
-
Research Site
RECRUITINGNew York, New York, 10016, United States
-
Research Site
RECRUITINGHouston, Texas, 77030, United States
-
Research Site
RECRUITINGRichmond, Virginia, 23298, United States
-
Research Site
WITHDRAWNSeattle, Washington, 98109, United States
-
Research Site
RECRUITINGMilwaukee, Wisconsin, 53226, United States
-
Research Site
RECRUITINGMelbourne, 3000, Australia
-
Research Site
SUSPENDEDPorto Alegre, 90035903, Brazil
-
Research Site
SUSPENDEDSão Paulo, 01401-002, Brazil
-
Research Site
SUSPENDEDSão Paulo, 05652-900, Brazil
-
Research Site
SUSPENDEDToronto, Ontario, M5G 2M9, Canada
-
Research Site
WITHDRAWNMontreal, Quebec, H3T1C5, Canada
-
Research Site
WITHDRAWNMontreal, Quebec, H4A 3J1, Canada
-
Research Site
RECRUITINGChangsha, 410008, China
-
Research Site
RECRUITINGChengdu, 610041, China
-
Research Site
RECRUITINGGuangzhou, 510060, China
-
Research Site
RECRUITINGGuangzhou, 510280, China
-
Research Site
RECRUITINGHangzhou, 310003, China
-
Research Site
RECRUITINGNanjing, 210008, China
-
Research Site
RECRUITINGNanjing, 210009, China
-
Research Site
RECRUITINGSuzhou, 215004, China
-
Research Site
RECRUITINGTianjin, 300020, China
-
Research Site
RECRUITINGZhengzhou, 450008, China
-
Research Site
SUSPENDEDCaen, 14033, France
-
Research Site
SUSPENDEDMarseille, 13009, France
-
Research Site
SUSPENDEDNantes, 44000, France
-
Research Site
SUSPENDEDParis, 75019, France
-
Research Site
SUSPENDEDPierre-Bénite, 69495, France
-
Research Site
SUSPENDEDToulouse, 31059, France
-
Research Site
SUSPENDEDCologne, 50924, Germany
-
Research Site
SUSPENDEDDüsseldorf, 40225, Germany
-
Research Site
WITHDRAWNEssen, 45147, Germany
-
Research Site
SUSPENDEDFrankfurt, 60590, Germany
-
Research Site
SUSPENDEDFreiburg im Breisgau, 79106, Germany
-
Research Site
SUSPENDEDHalle, 06120, Germany
-
Research Site
SUSPENDEDHamburg, 20246, Germany
-
Research Site
SUSPENDEDKiel, 24105, Germany
-
Research Site
SUSPENDEDMünchen, D-81337, Germany
-
Research Site
SUSPENDEDMünster, 48149, Germany
-
Research Site
SUSPENDEDWürzburg, 97080, Germany
-
Research Site
SUSPENDEDBergamo, 24127, Italy
-
Research Site
SUSPENDEDBologna, 40138, Italy
-
Research Site
SUSPENDEDMonza, 20900, Italy
-
Research Site
SUSPENDEDNaples, 80123, Italy
-
Research Site
SUSPENDEDRoma, 00165, Italy
-
Research Site
RECRUITINGBunkyō City, 113-8677, Japan
-
Research Site
RECRUITINGChiba, 260-8677, Japan
-
Research Site
RECRUITINGChūōku, 104-0045, Japan
-
Research Site
RECRUITINGFukuoka, 810-8563, Japan
-
Research Site
RECRUITINGKashiwa, 277-8577, Japan
-
Research Site
RECRUITINGKyoto, 606-8507, Japan
-
Research Site
RECRUITINGOkayama, 701-1192, Japan
-
Research Site
RECRUITINGOsaka, 545-8586, Japan
-
Research Site
RECRUITINGSapporo, 003-0006, Japan
-
Research Site
RECRUITINGToyohashi, 441-8570, Japan
-
Research Site
RECRUITINGYamagata, 990-9585, Japan
-
Research Site
RECRUITINGSeoul, 03080, South Korea
-
Research Site
RECRUITINGSeoul, 03722, South Korea
-
Research Site
RECRUITINGSeoul, 06351, South Korea
-
Research Site
RECRUITINGSeoul, 6591, South Korea
-
Research Site
SUSPENDEDBarcelona, 08036, Spain
-
Research Site
SUSPENDEDBarcelona, 8035, Spain
-
Research Site
SUSPENDEDMadrid, 28025, Spain
-
Research Site
SUSPENDEDMadrid, 28046, Spain
-
Research Site
SUSPENDEDSalamanca, 37007, Spain
-
Research Site
ACTIVE_NOT_RECRUITINGValencia, 46026, Spain
-
Research Site
SUSPENDEDKaohsiung City, 833401, Taiwan
-
Research Site
SUSPENDEDTaichung, 40705, Taiwan
-
Research Site
SUSPENDEDTainan, 70403, Taiwan
-
Research Site
SUSPENDEDTaipei, 10002, Taiwan
-
Research Site
SUSPENDEDTaoyuan, 333, Taiwan
-
Research Site
SUSPENDEDLondon, EC1A 7BE, United Kingdom
-
Research Site
SUSPENDEDManchester, M20 4BX, United Kingdom
-
Research Site
SUSPENDEDSurrey, SM1 2DL, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
- Can targeted drugs blinatumomab and venetoclax improve outcomes for childhood leukemia?
- Leukemia treatment may erase vaccine protection—study tests if re-vaccination works
- New cell therapy JY231 targets tough leukemia in early human test
- New CAR T-Cell therapy shows promise for kids with tough leukemia
- Experimental cell therapy targets tough blood cancers and anemia